This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
Researchers have created a new method to predict the risk that a woman will develop lymphedema within five years after lymph nodes are removed as part of breast cancer treatment. Lymphedema is an abnormal buildup of fluid following lymph node removal, specifically in the arm for women with breast cancer who had the axillary or underarm lymph nodes removed (called axillary lymph node dissection). It affects approximately four million patients worldwide, and it's currently very difficult to predict who will develop lymphedema.
In a recent analysis of information from nearly 6,000 women with breast cancer, researchers found that women younger than 50 were more likely to be diagnosed with breast cancer by feeling the tumor in the breast (called palpation) than with mammography when compared with women older than 50. This study used a statewide breast cancer registry from the Michigan Breast Oncology Quality Initiative to look at breast cancer diagnosis and treatment information to find out how the 2009 changes to the U.S. Preventive Services Task Force (USPSTF) breast cancer screening recommendations might affect how women find breast cancer, particularly those between ages 40 and 49. The USPSTF recommends that mammograms should be given every two years for women ages 50 to 74, and that women age 40 to 49 should not be offered regular mammography but should discuss the risks and benefits with their doctors. The recommendations also discourage teaching breast self-examination.
In a recent study, researchers found that radiation therapy to the regional lymph nodes decreases recurrences (cancers that come back after treatment) for women with early-stage breast cancer that has spread or is likely to spread to the lymph nodes. Regional lymph nodes are the lymph nodes near where the tumor started. For breast cancer, these are the lymph nodes in the armpit on the same side of the body where the cancer began, called the axillary lymph nodes.
A recent study showed that women who have been through menopause and have a high risk of breast cancer were less likely to develop the disease when they received an aromatase inhibitor (AI) called exemestane (Aromasin). An AI is a drug that reduces the amount of the hormone estrogen in a woman's body by stopping tissues and organs other than the ovaries from producing it. Previous research has shown that estrogen may help breast cancer grow. Drugs that block estrogen, such as tamoxifen (Nolvadex) and raloxifene (Evista), have been approved by the U.S. Food and Drug Administration to lower the risk of breast cancer for women at high risk for the disease. However, there is a risk of rare but serious side effects, such as uterine cancer and blood clots, with these two drugs. Researchers designed this study to find another option to lower breast cancer risk with fewer side effects.
An evaluation of the lifestyle habits of more than 13,000 healthy women with a high risk of breast cancer showed that the risk of breast, lung, and colon cancers is higher for women who have smoked for a long time, compared with women who did not smoke or who smoked for a shorter time.